News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Millennium Biotechnologies, Inc. Announces $200,000 Purchase Order From Greek Distributor Nutrimedica


4/1/2008 10:35:30 AM

BASKING RIDGE, N.J., April 1, 2008 /PRNewswire/ -- Millennium Biotechnologies, Inc., a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. , today reports the receipt of a $200,000 one year purchase order for the international distribution of the Resurgex(R) line in Greece. Millennium received the purchase order from Nutrimedica which is headquartered in Athens, Greece. Nutrimedica has served as Millennium's International Distribution Partner into Greece for the past two years. They have committed to purchase over $200,000 of Resurgex products for distribution into Greece in 2008.

This commitment to purchase over $200,000 of Resurgex(R) products for the Greek Market supported by a year to date purchase rate further enhances news released by Millennium in January of 2008 which reported overall sales in the Greek Market has increased from $30,000 in 2006 to $50,000 in 2007. These sales will now exceed $200,000 for 2008 which adds to the further expansion of Resurgex(R) product line into the international marketplace.

Nutrimedica has already imported and distributed Resurgex(R) products to hospitals, pharmacies, and direct to patients in Greece. Nutrimedica reports that the continued use of the Resurgex product line in Greece supports and encourages their expectation that the product line will be successful in the international marketplace.

Nutrimedica has been successful in broadening the usage of the Resurgex product line beyond Oncology, into other hospital settings including Intensive Care Units and Surgery Clinics.

About Millennium:

Millennium's six marketed products form the Company's advanced line of nutritional formulas. Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium also created Surgex(TM) sports nutrition formula, clinically proven to address the nutritional concerns of professional, Olympic, and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immuno-compromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function. Millennium's most recent formula is a contribution to the long term care market. Resurgex Essential(TM) and Resurgex Essential Plus(TM) are comprehensive, calorically dense formulas that meet and succeed the nutritional requirements of the assisted living community.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC"). These statements have not been evaluated by the Food and Drug Administration. Resurgex(R), Resurgex Plus(R), Resurgex Select(R) and Surgex(TM) are not intended to diagnose, treat, cure, or prevent and disease.

CONTACT: Jerry Swon of Millennium Biotechnologies, Inc., +1-908-604-2500


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES